SEC Filing - Acadia Pharmaceuticals Inc.

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

GORDON CARL L

(Last)

(First)

(Middle)

767 THIRD AVENUE

(Street)

NEW YORK

10017

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
05/26/2004

3. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series E Convertible Preferred Stock	⁽¹⁾	⁽²⁾	Common Stock	253,828	⁽³⁾	I⁽⁴⁾	By Eaton Vance Worldwide Health Sciences Fund
Series F Convertible Preferred Stock	⁽¹⁾	⁽²⁾	Common Stock	277,778	⁽³⁾	I⁽⁴⁾	By Eaton Vance Worldwide Health Sciences Fund
Series E Convertible Preferred Stock	⁽¹⁾	⁽²⁾	Common Stock	169,218	⁽³⁾	I⁽⁴⁾	By Finsbury Worldwide Pharmaceutical Trust
Series F Convertible Preferred Stock	⁽¹⁾	⁽²⁾	Common Stock	185,185	⁽³⁾	I⁽⁴⁾	By Finsbury Worldwide Pharmaceutical Trust
Stock Option (Right to Buy)	⁽¹⁾	06/12/2010	Common Stock	1,000	2	I	See footnote⁽⁵⁾
Stock Option (Right to Buy)	⁽¹⁾	12/04/2010	Common Stock	1,000	4	I	See footnote⁽⁵⁾
Stock Option (Right to Buy)	⁽¹⁾	02/26/2011	Common Stock	1,000	8	I	See footnote⁽⁵⁾

Explanation of Responses:

1. Immediate

2. These securities are preferred stock of the issuer and do not have an expiration date.

3. One for one.

4. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner ot the securities for purposes of Section 16 or any other purpose.

5. 60% beneficially owned by Eaton Vance Worldwide Health Sciences Fund and 40% beneficially owned by Finsbury Worldwide Pharmaceutical Trust.

Remarks:

	Carl L. Gordon	05/26/2004
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.